Abiopharma

🔍 Ryan Jason (Executive)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2025-08-27

Detailed Transactions and Holdings:

• Sold 8,818 shares of Class A Common Stock at $125.0729 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 132,538.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 8,969 shares of Class A Common Stock at $126.1536 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 123,569.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 5,443 shares of Class A Common Stock at $127.4373 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 118,126.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 3,452 shares of Class A Common Stock at $128.0408 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 114,674.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 9,890 shares of Class A Common Stock at $129.5945 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 104,784.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 1,500 shares of Class A Common Stock at $130.0103 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 103,284.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Sold 1,150 shares of Class A Common Stock at $129.6461 per share (Direct)
  Date: 2025-08-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 11,904.00 | transaction_form_type: 4 | Footnotes: F8

Footnotes:

• F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.50 to $125.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: The reporting person is the trustee of the Jason Ryan 2024 GRAT Trust U/A DTD 11/7/2024 (the "GRAT"), and the reporting person is the sole annuitant of the GRAT. The reporting person remains the beneficial owner of the securities held by the GRAT.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.655 to $126.62 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.76 to $127.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.76 to $128.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.89 to $129.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.91 to $130.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.50 to $129.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.